// App-Quantinova.ai

401 : Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑Cell Lymphoma

Researchers

Presenter

  • Adam J Olszewski

Principal Investigators

  • Abraham Avigdor

  • Sunil Babu

  • Itai Levi

  • Uri Abadi

  • Houston Holmes

  • Matthew McKinney

  • Ron McCord

  • Yuying Xie

  • Cindy Chen

  • Kati Sarouei

  • Naseer Qayum

  • Carol OHear

  • Gila Sellam

  • Herbert Eradat

Medical Centers

  • Brown University Urology, Providence, RI

  • Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN

  • Soroka University Medical Center, Beer Sheva, Israel

  • Meir Medical Center, Kfar-Saba, Israel

  • Texas Oncology, Dallas, TX

  • Duke Cancer Institute, Durham, NC

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • University of Southern California, Los Angeles, CA

Locations

  • United States

  • Israel

  • Canada

  • United Kingdom

  • Switzerland

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Plasma Renin Activity

Drug/Treatment

  • Vincristine

  • Prednisone

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • I/II

Study Id's

  • NCT02500407

  • NCT03677154

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved